DK1105122T3 - Pharmaceutical compositions containing lipase inhibitors - Google Patents

Pharmaceutical compositions containing lipase inhibitors

Info

Publication number
DK1105122T3
DK1105122T3 DK99940127T DK99940127T DK1105122T3 DK 1105122 T3 DK1105122 T3 DK 1105122T3 DK 99940127 T DK99940127 T DK 99940127T DK 99940127 T DK99940127 T DK 99940127T DK 1105122 T3 DK1105122 T3 DK 1105122T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
compositions containing
lipase inhibitors
containing lipase
inhibitors
Prior art date
Application number
DK99940127T
Other languages
English (en)
Inventor
Hans-Peter Maerki
Manuela Hug
Marcel Meier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1105122T3 publication Critical patent/DK1105122T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Jellies, Jams, And Syrups (AREA)
DK99940127T 1998-08-14 1999-08-02 Pharmaceutical compositions containing lipase inhibitors DK1105122T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98115311 1998-08-14
EP99109516 1999-05-12
EP99940127A EP1105122B1 (en) 1998-08-14 1999-08-02 Pharmaceutical compositions containing lipase inhibitors

Publications (1)

Publication Number Publication Date
DK1105122T3 true DK1105122T3 (da) 2005-08-08

Family

ID=26149537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99940127T DK1105122T3 (da) 1998-08-14 1999-08-02 Pharmaceutical compositions containing lipase inhibitors

Country Status (19)

Country Link
US (1) US6358522B1 (da)
EP (1) EP1105122B1 (da)
JP (1) JP3774118B2 (da)
KR (1) KR20010079635A (da)
CN (1) CN1170534C (da)
AR (1) AR035001A1 (da)
AT (1) ATE293970T1 (da)
AU (1) AU761351B2 (da)
BR (1) BR9912980B1 (da)
CA (1) CA2340056C (da)
CO (1) CO5130009A1 (da)
DE (1) DE69924999T2 (da)
DK (1) DK1105122T3 (da)
ES (1) ES2242413T3 (da)
MA (1) MA26671A1 (da)
PE (1) PE20000953A1 (da)
PT (1) PT1105122E (da)
TR (1) TR200100471T2 (da)
WO (1) WO2000009122A1 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
JP2002524410A (ja) 1998-09-08 2002-08-06 スミスクライン・ビーチャム・コーポレイション リプスタチン誘導体−可溶性繊維錠剤
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
CZ301813B6 (cs) 2000-06-27 2010-06-30 F. Hoffmann-La Roche Ag Zpusob prípravy farmaceutické kompozice
ES2240516T3 (es) * 2000-07-28 2005-10-16 F. Hoffmann-La Roche Ag Nuevo uso de los inhibidores de lipasa.
PL204443B1 (pl) * 2000-07-28 2010-01-29 Hoffmann La Roche Kompozycja farmaceutyczna zawierająca inhibitor lipazy, sposób wytwarzania kompozycji farmaceutycznej, zestaw do leczenia otyłości, zastosowanie kompozycji farmaceutycznej oraz zastosowanie orlistatu i substancji wiążącej kwasy żółciowe
CA2417607C (en) 2000-08-09 2008-01-29 Christine Feinle Lipase inhibitors for the treatment of dyspepsia
CA2422698C (en) 2000-10-16 2009-12-15 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
CA2432085C (en) 2000-12-27 2009-02-24 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
MXPA03010565A (es) 2001-05-21 2004-03-02 Hoffmann La Roche Derivados de quinolina como ligandos para receptor del neuropeptido y.
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
PL372295A1 (en) 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
JP2005526732A (ja) 2002-02-28 2005-09-08 エフ．ホフマン−ラ　ロシュ　アーゲー Ｎｐｙ受容体拮抗剤としてのチアゾール誘導体
WO2003090742A1 (en) 2002-04-26 2003-11-06 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a lipase inhibitor and glucomannan
BR0312461A (pt) 2002-07-05 2005-04-26 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e métodos para tratamento e profilaxia
EP1539722A1 (en) 2002-08-07 2005-06-15 F. Hoffmann-La Roche Ag Thiazole derivatives
MXPA05002704A (es) 2002-09-12 2005-05-05 Hoffmann La Roche Compuestos de acido n-sustituido-1h-indol-5-propionico como agonistas de los receptores activados proliferadores de peroxisomas (ppar) utiles para el tratamiento de diabetes.
ES2312819T3 (es) 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
ES2297437T3 (es) 2003-08-12 2008-05-01 F. Hoffmann-La Roche Ag Npy-antagonistas de 2-amino-5-benzoiltiazol.
BRPI0413458A (pt) 2003-08-12 2006-10-17 Hoffmann La Roche compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
ATE514698T1 (de) 2005-05-03 2011-07-15 Hoffmann La Roche Tetracyclische azapyrazinoindoline als 5-ht2- liganden
US20090208584A1 (en) * 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
EP1945635B1 (en) 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
JP4879996B2 (ja) 2005-11-30 2012-02-22 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３調節剤として使用するための１，１−ジオキソ−チオモルホリニルインドリルメタノン誘導体
ES2342979T3 (es) 2005-11-30 2010-07-20 F. Hoffmann-La Roche Ag Derivados de indol-2-carboxamida sustituidos en 5.
DE602006020482D1 (de) 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
ATE448230T1 (de) 2005-12-09 2009-11-15 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
AU2006326135A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
CN101331131A (zh) 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
EP2032554A1 (en) 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Piperidinyl pyrimidine derivatives
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
NZ580891A (en) * 2007-05-16 2012-06-29 Buckman Labor Inc Methods to control organic contaminants in fibers in paper making systems
EP2183237A1 (en) 2007-07-25 2010-05-12 F. Hoffmann-Roche AG Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
MX2010004072A (es) * 2007-10-15 2010-09-14 Inventis Dds Pvt Ltd Composicion farmaceutica de orlistat.
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
WO2017218230A1 (en) * 2016-06-17 2017-12-21 The Procter & Gamble Company Soft chewable composition comprising psyllium
CN112220831A (zh) * 2020-08-07 2021-01-15 天津盛实百草中药科技有限公司 圆苞车前子壳粉在缓解奥利司他副作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JPH09252746A (ja) * 1996-03-22 1997-09-30 Nippon Kankyo Yakuhin Kk 栄養補助食品
JP4202439B2 (ja) * 1996-10-01 2008-12-24 江崎グリコ株式会社 フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
ES2242413T3 (es) 2005-11-01
ATE293970T1 (de) 2005-05-15
AU5418599A (en) 2000-03-06
CN1312713A (zh) 2001-09-12
JP2002522491A (ja) 2002-07-23
JP3774118B2 (ja) 2006-05-10
EP1105122B1 (en) 2005-04-27
PT1105122E (pt) 2005-08-31
EP1105122A1 (en) 2001-06-13
WO2000009122A1 (en) 2000-02-24
CA2340056A1 (en) 2000-02-24
TR200100471T2 (tr) 2001-07-23
KR20010079635A (ko) 2001-08-22
US6358522B1 (en) 2002-03-19
AU761351B2 (en) 2003-06-05
DE69924999T2 (de) 2006-05-04
BR9912980A (pt) 2001-05-08
CA2340056C (en) 2007-01-09
MA26671A1 (fr) 2004-12-20
PE20000953A1 (es) 2000-09-26
DE69924999D1 (de) 2005-06-02
AR035001A1 (es) 2004-04-14
BR9912980B1 (pt) 2013-10-22
CN1170534C (zh) 2004-10-13
CO5130009A1 (es) 2002-02-27

Similar Documents

Publication Publication Date Title
DK1105122T3 (da) Pharmaceutical compositions containing lipase inhibitors
PT1105123E (pt) Composicoes farmaceuticas contendo inibidores da lipase e quitosano
EE200000488A (et) Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
IS5046A (is) Lyfjasamsetningar
PT1066027E (pt) Composicao farmaceutica de topiramato
ID27415A (id) Komposisi farmaseutik
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
MA26818A1 (fr) Formulations contenant des inhibiteurs de lipase
DE69836106D1 (de) Stanolester enthaltende Zusammensetzungen
HK1053787A1 (zh) 含有hiv蛋白酶抑制劑的藥物組合物
ID18352A (id) Komposisi-komposisi farmasi
ID29262A (id) Komposisi farmasi
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
ID27201A (id) Komposisi farmasi
EE9800400A (et) Diklofenaaki sisaldavad farmatseutilised kompositsioonid
PT969815E (pt) Composicoes farmaceuticas
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
EE200000330A (et) Farmatseutilised kompositsioonid
IS2200B (is) Lyfjasamsetningar
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
NO994436D0 (no) Farmasöytiske sammensetninger
ZA200100696B (en) Pharmaceutical compositions containing lipase inhibitors
SE9800052D0 (sv) Pharmaceutical compositions